LIVE: FDA Vaccines Advisory Committee Meets on Moderna's mRNA Influenza Vaccine MFLUSIVA

Live News Network
Live News Network
1.4K followers
89 Video Views·Jun 18, 2026

The FDA Vaccines and Related Biological Products Advisory Committee holds a meeting at 8:30 a.m. ET on June 18 to discuss and make recommendations on the safety and effectiveness of MFLUSIVA (Influenza Vaccine, mRNA), manufactured by Moderna TX Inc., with a requested indication in Biologics License Application STN 125869/0 for the prevention of influenza disease caused by influenza virus subtypes A and B represented in the vaccine, in persons 50 years of age and older.